title: Clinical report of intra-arterial interventional chemotherapy for synovial sarcoma on limbs.
abstract: OBJECTIVE
  The efficiency of implantable intra-arterial interventional chemotherapy before the operation for synovial sarcoma on limbs was evaluated.
  
  
  METHODS
  Drug delivery device (chemotherapy pumps) was implanted percutaneously for 36 patients, and the interventional chemotherapy was conducted for 3-4 cycles. The surgical resection was carried out after obvious improvement was observed by clinical and imaging examination. The evaluation standard for the efficiency of chemotherapy was tumor cell necrosis rate obtained from postoperative pathological test.
  
  
  RESULTS
  The response rate (RR) of pain alleviation was 91% (32/36), and the RR of the changing of lesion imaging was 83% (30/36). Thirty cases received extensive tumor excision, and six cases received amputation because of poor response to tumor chemotherapy and local carcinelcosis. The postoperative pathological test showed 81% moderate and severe chemotherapy response (29/36). The average follow-up time was 39 months. There were three cases presenting with local tumor recurrence, and seven deaths due to pulmonary metastasis.
  
  
  CONCLUSIONS
  Intra-arterial interventional chemotherapy before operation for synovial sarcoma can effectively control pain. After chemotherapy, the imaging performance significantly changed, and tumor cells were necrotized extensively. The pathological changes were obvious.
authors.forename: Qiu
authors.initials: Q
authors.lastname: Cui
authors.affiliation: Department of Orthopedics, Affiliated Hospital of Academy of Military Medical Sciences, PLA 307th Hospital, Beijing, China.
authors.forename: Dingfeng
authors.initials: D
authors.lastname: Li
authors.forename: Shubin
authors.initials: S
authors.lastname: Liu
authors.forename: Weihao
authors.initials: W
authors.lastname: Jiang
authors.forename: Jun
authors.initials: J
authors.lastname: Guo
authors.forename: Cheng
authors.initials: C
authors.lastname: Liu
authors.forename: Yaosheng
authors.initials: Y
authors.lastname: Liu
authors.forename: Ping
authors.initials: P
authors.lastname: Zhang
authors.forename: Haitao
authors.initials: H
authors.lastname: Fan
authors.forename: Lei
authors.initials: L
authors.lastname: Wang
authors.forename: Bin
authors.initials: B
authors.lastname: Zhang
authors.affiliation: Biomechanics and Medical Information Institute, Beijing University of Technology, Beijing, China.
authors.forename: Yanjun
authors.initials: Y
authors.lastname: Zeng
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols; D002648:Child; D003131:Combined Modality Therapy; D004317:Doxorubicin / Q000008:administration & dosage; D005121:Extremities / Q000473:pathology / Q000601:surgery*; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy / Q000473:pathology* / Q000556:secondary; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000473:pathology*; D013584:Sarcoma, Synovial / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D055815:Young Adult
chemical_list: D004317:Doxorubicin